Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: 25th European Workshop for Rheumatology Research

Poster presentation

Quantitative and qualitative analysis of CD4+CD25+ regulatory T cells in systemic lupus erythematosus patients

M Bonelli, JS Smolen and C Scheinecker

Author Affiliations

Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria

For all author emails, please log on.

Arthritis Research & Therapy 2005, 7(Suppl 1):P102  doi:10.1186/ar1623

The electronic version of this article is the complete one and can be found online at:


Received:11 January 2005
Published:17 February 2005

© 2005 BioMed Central Ltd

Poster presentation

CD4+CD25+ regulatory T cells (Treg) that specialize in the suppression of immune responses play a critical role in the regulation of peripheral immune tolerance and thus might be critically involved in the pathogenesis of autoimmune diseases. As for systemic lupus erythematosus (SLE), however, data concerning Treg are so far limited. We therefore initiated detailed quantitative and qualitative analysis of naturally occurring CD4+CD25+ Treg from SLE patients as compared with healthy controls. FACS analysis revealed increased proportions of CD4+CD25+ Treg, as well as activated CD4+CD69+ T cells, among peripheral blood mononuclear cells in SLE patients as compared with healthy controls. Ongoing experiments aim to analyze the capacity of purified CD4+CD25+ Treg to suppress the proliferation of autologous or allogeneic T cells. Preliminary results indicate a tendency towards a reduced suppressive capacity of CD4+CD25+ Treg in SLE patients as compared with healthy controls. Additional experiments will determine the statistical significance of this observation and will correlate quantitative and/or qualitative defects of Tregs in SLE patients with clinical data. Finally, this study will also allow one to experimentally abrogate potential defects of Treg in SLE patients. This might provide the basis for new therapeutic concepts in the treatment of SLE and other autoimmune diseases.